Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.
For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM) also to be reviewed WALTHAM, Mass. and BOULDER, Colo., Dec.
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer